乳腺癌患者肿瘤转移相关基因1表达与化疗敏感性及预后的相关性

Correlation of Tumor Metastasis-Associated Gene 1 Expression with Chemotherapy Sensitivity and Prognosis in Breast Cancer Patients

目的研究乳腺癌患者肿瘤转移相关基因1(MTA1)表达与化疗敏感性及预后的相关性。方法选取92例接受乳腺癌根治术的患者作为研究对象,根据患者术后化疗结果分为敏感组和抵抗组,比较2组患者的MTA1表达水平以及相关病理参数,采用logistic回归分析影响患者化疗敏感性的因素,同时根据随访结果分析MTA1表达水平与患者预后的相关性。结果92例化疗患者中敏感组患者共53例,抵抗组共39例。敏感组患者MTA1高表达率低于抵抗组(P<0.05)。敏感组患者中年龄<55岁、KPS评分≥80分、肿瘤分期Ⅰ/Ⅱ期患者占比高于抵抗组(P<0.05)。Logistic回归分析结果显示年龄≥55岁、Karnofsky功能状态评分(KPS)<80分、肿瘤分期Ⅲ期以及MTA1高表达状态均是影响化疗敏感性的高危因素(P<0.05)。MTA1高表达组中位PFS为8个月以及中位OS为13个月,低表达组的中位PFS为12个月以及中位OS为16.5个月,差异比较具有统计学意义(P<0.05)。结论乳腺癌患者MTA1表达与化疗效果有关,其高表达提示化疗不敏感和预后不良,可能成为预测患者预后的重要指标。

Objective To explore the correlation of tumor metastasis-associated gene 1(MTA1)expression with chemotherapy sensitivity and prognosis in breast cancer patients.Methods 92 patients underwent radical mastectomy for breast cancer were enrolled,and patients were classified into sensitive group(n=53)and resistance group(n=39)according to the results of postoperative chemotherapy.MTA1 expression levels as well as related pathological parameters were compared between two groups.Logistic regression analysis was used to screen the factors affecting the chemosensitivity of the patients,furthermore,the correlation between MTA1 expression levels and prognosis was discussed according to the patient follow-up results.Results Among the 92 chemotherapy patients,53 patients were in the sensitive group and 39 patients were in the resistant group.MTA1 was overexpressed in 13 patients and underexpressed in 40 patients in sensitive group,and overexpressed in 22 and underexpressed in 17 cases in resistant group.The overexpression rate of MTA1 in sensitive group was lower than that in resistance group(P<0.05).The proportion of patients aged<55 years,scored≥80 on Karnofsky Performance Scale(KPS)scale and tumor stage Ⅰ/Ⅱ in sensitive group was larger than in resistant group(P<0.05).Logistic regression analysis denoted that age≥55 years,KPS score<80,tumour stage and MTA1 overexpression were all high risk factors for chemotherapy sensitivity(P<0.05).The median progression-free survival(PFS)and overall survival(OS)were 8 months and 13 months in MTA1 overexpression group,and 12 months and 16.5 months in underexpression group,with statistical difference(P<0.05).Conclusion MTA1 expression in breast cancer patients is associated with chemotherapy effect,and its overexpression is suggestive of insensitivity to chemotherapy and poor prognosis,and may be an important predictor of patient's prognosis.